长春高新(000661.SZ)：注射用GenSci140境内生产药品注册临床试验申请获受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of GenSci140, a new targeted drug developed by the company [1] Group 1 - GenSci140 is a novel bispecific antibody-drug conjugate targeting the folate receptor alpha (FRα), composed of Fab fragments binding to different epitopes of FRα and a single-domain heavy chain antibody (VHH) [1] - The drug utilizes a cleavable linker and is loaded with a topoisomerase I (TOPOI) inhibitor, enhancing its therapeutic potential [1] - GenSci140 can bind to two different epitopes expressed on tumor cells, increasing antibody binding and internalization, which promotes the delivery of the TOPOI cytotoxic payload into the cells, leading to direct tumor cell killing [1]